FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)

被引：0
|
作者：
Le, Xiuning
Spira, Alexander I.
Gadgeel, Shirish M.
Riess, Jonathan W.
Yu, Yan
Zhao, Yanqiu
Cheng, Ying
Juan-Vidal, Oscar
Gao, Bo
Yoh, Kiyotaka
Forster, Martin
Kitazono, Satoru
Hayashi, Hidetoshi
Planchard, David
Jiang, Yong
Baio, Nichole
Kowanetz, Marcin
Leung, William
Hsu, Jerry Y.
Wang, Jie
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] NEXT Oncol Virginia, Fairfax, VA USA
[3] Henry Ford Hlth, Henry Ford Canc Inst, Detroit, MI USA
[4] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
[5] Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
[7] Jilin Canc Hosp, Changchun, Peoples R China
[8] Hosp Univ Politecn La Fe, Valencia, Spain
[9] Blacktown Hosp, Blacktown Canc & Haematol Ctr, Blacktown, NSW, Australia
[10] Natl Canc Ctr Hosp East, Kashiwa, Japan
[11] UCL, Hosp NHS Trust, Canc Inst, London, England
[12] Japanese Fdn Canc Res JFCR, Canc Inst Hosp, Tokyo, Japan
[13] Kindai Univ Hosp, Osaka, Japan
[14] Gustave Roussy, Dept Med Oncol, Thorac Grp, Villejuif, France
[15] Allist Pharmaceut, Shanghai, Peoples R China
[16] ArriVent Biopharma, Newtown, PA USA
[17] ArriVent Biopharma, Burlingame, CA USA
[18] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8666
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
    Christopoulos, Petros
    Herster, Franziska
    Hoffknecht, Petra
    Falk, Markus
    Tiemann, Markus
    Kopp, Hans-Georg
    Althoff, Andre
    Stammberger, Anja
    Laack, Eckart
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A RealWorld Study
    Yan, N. N.
    Guo, S.
    Huang, S.
    Zhang, H.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S622 - S622
  • [43] Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)
    Cheema, P.
    Passaro, A.
    Martin, C.
    Tiseo, M.
    Park, K.
    Chang, G.
    Hu, Y.
    Cho, B. C.
    Miranda, M.
    Fernandes, A.
    Freitas, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S854 - S854
  • [44] FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
    Le, X.
    Yu, Y.
    Zhao, Y.
    Planchard, D.
    Cheng, Y.
    Li, X.
    Gadgeel, S.
    Zhang, J.
    Spira, A.
    Hayashi, H.
    Riess, J.
    Kitazono, S.
    Leighl, N.
    Gao, B.
    Juan-Vidal, O.
    de Langen, A. J.
    Mazieres, J.
    Perol, M.
    Jiang, Y.
    Hu, T.
    Huang, J.
    Baio, N.
    Musib, L.
    Kowanetz, M.
    Wang, S.
    Leung, W.
    Yea, S.
    Hsu, J.
    Wang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S5 - S6
  • [45] Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area
    Zhang, J. Q.
    Feng, J. G.
    Liu, T.
    Zhang, X.
    Chen, X. B.
    Li, S. Y.
    Yuan, B.
    Xing, X. Q.
    Chai, Y. L.
    Jin, Z. X.
    Liang, Y. X.
    Xiao, Y.
    Li, M. H.
    Liu, L.
    Fang, L. Z.
    Shu, J. K.
    Zhang, J. Q.
    Jia, M.
    Li, Z. K.
    Li, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S673 - S673
  • [46] Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study
    Qin, Yi
    Long, Yaling
    Tang, Yuan
    Tian, Yuke
    Li, Juan
    Duan, Ping
    Luo, Jieyan
    Yu, Min
    Li, Yanying
    Zhou, Xiaojuan
    Wang, Ke
    Gong, Youling
    Peng, Feng
    Zhu, Jiang
    Liu, Yongmei
    Zhou, Lin
    Lu, You
    Huang, Meijuan
    CANCER SCIENCE, 2023, 114 (06) : 2552 - 2559
  • [47] Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
    Yang, Shuo
    Mao, Shiqi
    Li, Xuefei
    Zhao, Chao
    Liu, Qian
    Yu, Xiaofei
    Wang, Yan
    Liu, Yiwei
    Pan, Yingying
    Wang, Chunyan
    Gao, Guanghui
    Li, Wei
    Xiong, Anwen
    Chen, Bin
    Sun, Hui
    He, Yayi
    Wu, Fengying
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2020, 139 : 133 - 139
  • [48] Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study
    Soo, Ross A.
    Reungwetwattana, Thanyanan
    Perroud, Herman Andres
    Batra, Ullas
    Kilickap, Saadettin
    Gallegos, Luis Fernando Tejado
    Donner, Natalia
    Alsayed, Mohamed
    Huggenberger, Reto
    Tu, Dao Van
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : 1449 - 1459
  • [49] A Phase 1, 2 Study to Evaluate the Safety and Antitumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC
    Lim, S. M.
    Cho, B. C.
    Nagasaka, M.
    Reungwetwattana, T.
    Jo, A.
    Seah, E.
    Kim, C.
    Ou, S. -H. I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S335 - S335
  • [50] Rare and Common EGFR Mutations in Patients with Advanced NSCLC Treated with EGFR-TKIs: A Registry-Based Study
    Pesek, Milos
    Kolek, Vitezslav
    Skrickova, Jana
    Cernovska, Marketa
    Koubkova, Leona
    Roubec, Jaromir
    Salajka, Frantisek
    Zemanova, Milada
    Krejci, Jana
    Hejduk, Karel
    Ryska, Ales
    Minarik, Marek
    Fiala, Ondrej
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S318 - S318
12345